Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TPST Tempest Therapeutics Inc.

Trading 02-25 15:17:09 EST

2.28

-0.21

-8.43%

High2.31	Low2.12	Vol630.98K
Open2.31	D1 Closing2.49	Amplitude7.63%
Mkt Cap11.23M	Tradable Cap10.60M	Total Shares4.93M
T/O1.41M	T/O Rate13.57%	Tradable Shares4.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TPST","market":"US","secType":"STK","nameCN":"Tempest Therapeutics Inc.","latestPrice":2.28,"timestamp":1772050512796,"preClose":2.49,"halted":0,"volume":630979,"delay":0,"changeRate":-0.08433734939759052,"floatShares":4650800,"shares":4927161,"eps":-10.103,"marketStatus":"Trading","change":-0.21,"latestTime":"02-25 15:17:09 EST","open":2.31,"high":2.31,"low":2.12,"amount":1413279.8254653001,"amplitude":0.076305,"askPrice":2.28,"askSize":123,"bidPrice":2.26,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-10.103,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772053200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":2.49,"preHourTrading":{"tag":"盘前","latestPrice":2.33,"preClose":2.49,"latestTime":"09:27 EST","volume":219335,"amount":538396.228859,"timestamp":1772029670022,"change":-0.16,"changeRate":-0.064257,"amplitude":0.297189},"postHourTrading":{"tag":"盘后","latestPrice":2.49,"preClose":2.49,"latestTime":"16:39 EST","volume":11,"amount":27.27,"timestamp":1771969142315,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":19.154531,"impliedVol":1.4125,"impliedVolPercentile":0.3548},"requestUrl":"/m/hq/s/TPST/wiki","defaultTab":"wiki","newsList":[{"id":"2614082668","title":"Tempest reports 100% complete response rate in interim REDEEM-1 trial of TPST-2003 CAR-T therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082668","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082668?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024355,"startTime":"0","endTime":"0","summary":"Tempest reports 100% complete response rate in interim REDEEM-1 trial of TPST-2003 CAR-T therapy               Tempest Therapeutics Inc. reported interim clinical data from the ongoing REDEEM-1 Phase ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL7hgbFQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","TPST","BK4139","SG9999014005.SGD","LU2095319765.USD","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","SG9999014039.USD","SG9999014021.USD","BK4112","LU0314104364.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2614970082","title":"Tempest Therapeutics Inc - Favorable Safety Profile With No Grade 3 or Higher Crs","url":"https://stock-news.laohu8.com/highlight/detail?id=2614970082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614970082?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA22XVGC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2614941082","title":"Tempest Therapeutics: Co Also Exploring Potential Development of Tpst-2003 to Include Patients With Lbcl, Other Related Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2614941082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614941082?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA22XVGC:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2614829460","title":"Tempest Therapeutics Inc - to Initiate U.S. Registrational Study in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614829460","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614829460?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA22XVGC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2614082961","title":"Tempest Therapeutics Inc - 100% Complete Response Rate Among All Six Efficacy Evaluable Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082961","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082961?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA22XVGC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2614082639","title":"Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082639","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082639?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":"100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244522/0/en/Tempest-Announces-Interim-Results-from-Ongoing-REDEEM-1-Trial-of-TPST-2003-Preparing-for-Potential-U-S-Registrational-Study-in-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","BK4006","CRS","BK4187","BK4230","IE00B19Z4B17.USD","PFS","IE00B7SZL793.SGD","IE0031619046.USD","CR","SLE","BK4022","BK4139","BK4211","BK4161","BK4195","LU0963586101.USD","LU2065731478.USD","CAR","TPST","EMD","BK4077"],"gpt_icon":0},{"id":"2610953407","title":"BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2610953407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610953407?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:04","pubTimestamp":1770818685,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation EnergyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL6N3Z70I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCD","SCCO","HNGE","HL","HOYY","SHOP","CEG","RIO.UK","CDE","HUM","GFS","FRSH","AMZW","NET","AMZY","R","AZYY","SHPU","MAT","AMZU","USAW.SI","AU","AMZD","BWA","TMUS","UPB","KHC","CURB","GILD","QXO","BETA","THC","AVTR","GLTO","MRNA","TPST","HOOG","NEM","BHP.AU","DTIL","FCX","AMZN","RIO.AU","AMZZ","HOOW","ROBN","LYFT","PSN","HOOD"],"gpt_icon":0},{"id":"2610937358","title":"BUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610937358","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610937358?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:39","pubTimestamp":1770813594,"startTime":"0","endTime":"0","summary":"BUZZ-Tempest Therapeutics rises on partnerfunded plan for new cancer drugs** Shares of cancer drug developer Tempest Therapeutics TPST.O rise 2.07% to $2.47 premarket** Co says it will focus on developing its newly acquired cancer programs, while keeping costs low through partner-funded trials** Co's TPST-2003, a dualtargeting CART for blood cancers, is already being tested in China; larger study expected end-2026 with early data in 2027 – co says** Co says TPST-4003 aims to treat cancer without complex cell manufacturing, plans to move it into early studies with partner support** Shares were down ~73% in 2025  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z710Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2610093109","title":"Tempest Therapeutics Outlines Future Plans to Advance Dual-Targeting CAR-T Programs, Expand In Vivo Pipeline, and Pursue Partner-Funded Development Strategies","url":"https://stock-news.laohu8.com/highlight/detail?id=2610093109","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610093109?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:59","pubTimestamp":1770811169,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Outlines Future Plans to Advance Dual-Targeting CAR-T Programs, Expand In Vivo Pipeline, and Pursue Partner-Funded Development Strategies. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL87nMpG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","BK4112","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","LU2095319765.USD","NDAQ","SG9999014039.USD","SG9999014021.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","TPST"],"gpt_icon":0},{"id":"2610934355","title":"Tempest Therapeutics Inc - Plans to Progress Additional Dual Targeting Tpst-3003 CAR-T Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2610934355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610934355?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:59","pubTimestamp":1770811140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA32STZ2:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2610493103","title":"Tempest Therapeutics Inc - Expects Phase 2B Initiation for Tpst-2003 by 2026 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2610493103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610493103?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:59","pubTimestamp":1770811140,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA32STZ2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2610088931","title":"Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2610088931","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610088931?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:59","pubTimestamp":1770811140,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA32STZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2609451511","title":"Tempest Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO and President Matthew Angel","url":"https://stock-news.laohu8.com/highlight/detail?id=2609451511","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609451511?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:25","pubTimestamp":1770413124,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc. has filed an initial statement of beneficial ownership. The filing lists Matthew Angel, who serves as CEO, President, Director, and a 10% owner, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL3wdMr1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempest Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO and President Matthew Angel","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2609511634","title":"Tempest Therapeutics kündigt Privatplatzierung und unregistrierten Aktienverkauf an","url":"https://stock-news.laohu8.com/highlight/detail?id=2609511634","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609511634?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:13","pubTimestamp":1770412392,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc. hat eine Privatplatzierung und einen unregistrierten Aktienverkauf bekannt gegeben. Im Rahmen einer Transaktion am 3. Februar 2026 wurden rund 8,3 Millionen neue Stammaktien an Erigen ausgegeben. Nach Abschluss dieser Ausgabe hlt Erigen etwa 61% der ausstehenden Stammaktien von Tempest Therapeutics, whrend die bisherigen Aktionre rund 39% besitzen. Die Aktien wurden gem einer Ausnahmeregelung des US-Wertpapiergesetzes im Rahmen eines privaten Angebots ausgegeben und sind nicht registriert.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL8Hx1kD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2609166143","title":"BRIEF-Tempest Announces Closing Of Strategic Acquisition Of Dual-Targeting Car-T Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2609166143","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609166143?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:47","pubTimestamp":1770241655,"startTime":"0","endTime":"0","summary":"BRIEF-Tempest Announces Closing Of Strategic Acquisition Of Dual-Targeting Car-T AssetsFeb 4 (Reuters) - Tempest Therapeutics Inc TPST.O:TEMPEST ANNOUNCES CLOSING OF STRATEGIC ACQUISITION OF DUAL-TARG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUA3FFHTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2609831665","title":"Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2609831665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609831665?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:47","pubTimestamp":1770241633,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUA3FFHTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2602930138","title":"Tempest Therapeutics Faces Nasdaq Delisting Notice Over Missed Annual Meeting Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2602930138","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602930138?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:16","pubTimestamp":1767993373,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc. is facing a regulatory issue related to its continued listing on the Nasdaq Stock Market. The company failed to hold its annual meeting of stockholders within twelve months of the end of its fiscal year on December 31, 2024, which is a requirement under Nasdaq Listing Rules 5620 and 5810. As a result, Nasdaq has notified Tempest Therapeutics of its non-compliance. The company has 45 days from January 8, 2026, to regain compliance or submit a plan to do so, and could be granted up to 180 days from the fiscal year end to resolve the issue. Holding the scheduled 2025 Annual Meeting would bring the company back into compliance with Nasdaq requirements.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1fHbHZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2588828068","title":"Tempest Therapeutics Inc. Announces Date for Upcoming Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588828068","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588828068?lang=en_us&edition=fundamental","pubTime":"2025-12-03 01:59","pubTimestamp":1764698385,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc. will hold its Annual Meeting of Stockholders on December 31, 2025. During the meeting, shareholders will vote on the election of the Board's Class I nominee, Geoff Nichol, to the Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL61gJGs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2586604302","title":"BRIEF-Tempest Announces Closing Of Up To $8.35 Million Registered Direct Offering Of Common Stock And Concurrent Private Placement Of Warrants Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2586604302","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586604302?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:12","pubTimestamp":1764191561,"startTime":"0","endTime":"0","summary":"BRIEF-Tempest Announces Closing Of Up To $8.35 Million Registered Direct Offering Of Common Stock And Concurrent Private Placement Of Warrants Priced At-The-Market Under Nasdaq RulesNov 26 (Reuters) -","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUA21MRVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2586609792","title":"Tempest Therapeutics Raises $8.35 Million Through Registered Direct Offering and Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2586609792","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586609792?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:05","pubTimestamp":1764191114,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc. announced the closing of a registered direct offering and a concurrent private placement, raising $4.25 million upfront. The company sold 1,172,414 shares of common stock at $3.625 per share in the registered direct offering. In the concurrent private placement, Tempest issued short-term unregistered warrants to purchase up to 1,172,414 shares of common stock at an exercise price of $3.50 per share. The warrants are immediately exercisable and will expire eighteen months after the effective date of the registration statement for the underlying shares. The private placement and the shares issuable upon exercise of the warrants were offered under Section 4 of the Securities Act of 1933 and/or Regulation D, and are not registered under the Act or applicable state securities laws. Up to an additional $4.1 million in gross proceeds may be raised if the warrants are fully exercised.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL3qYPxF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","TPST","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","LU0314104364.USD","BK4588","NDAQ","BK4139","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tempesttx.com","stockEarnings":[{"period":"1week","weight":0.0551},{"period":"1month","weight":-0.1644},{"period":"3month","weight":-0.2243},{"period":"6month","weight":-0.7472},{"period":"1year","weight":-0.78},{"period":"ytd","weight":-0.1324}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0113},{"period":"6month","weight":0.0592},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.008}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.012727},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.026988},{"month":3,"riseRate":0.5,"avgChangeRate":0.024061},{"month":4,"riseRate":0.25,"avgChangeRate":-0.140205},{"month":5,"riseRate":0.461538,"avgChangeRate":0.004949},{"month":6,"riseRate":0.307692,"avgChangeRate":-0.113246},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.025247},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.054209},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.059229},{"month":10,"riseRate":0.461538,"avgChangeRate":0.94597},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.081423},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.062561}],"exchange":"NASDAQ","name":"Tempest Therapeutics Inc.","nameEN":"Tempest Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tempest Therapeutics Inc.,TPST,Tempest Therapeutics Inc.股票,Tempest Therapeutics Inc.股票老虎,Tempest Therapeutics Inc.股票老虎国际,Tempest Therapeutics Inc.行情,Tempest Therapeutics Inc.股票行情,Tempest Therapeutics Inc.股价,Tempest Therapeutics Inc.股市,Tempest Therapeutics Inc.股票价格,Tempest Therapeutics Inc.股票交易,Tempest Therapeutics Inc.股票购买,Tempest Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction